Prospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 6, 2024; 12(19): 3866-3872
Published online Jul 6, 2024. doi: 10.12998/wjcc.v12.i19.3866
Hybrid argon plasma coagulation for the treatment of Barrett’s esophagus: A prospective, multicenter study
Dong Wang, Yan Chen, Feng Ji, Jian-Wei Hu, Ping-Hong Zhou, Shu-Chang Xu, Ying Chen, Li-Ping Ye, Guo-Liang Ye, Rui Li, Zhao-Shen Li
Dong Wang, Department of Gastroenterology, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200011, China
Yan Chen, Zhao-Shen Li, Department of Gastroenterology, Changhai Hospital, Shanghai 200438, China
Feng Ji, Department of Gastroenterology, The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou 311399, Zhejiang Province, China
Jian-Wei Hu, Ping-Hong Zhou, Endoscopy Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Shu-Chang Xu, Ying Chen, Endoscopy Center, Tongji Hospital of Tongji University, Shanghai 200092, China
Li-Ping Ye, Department of Gastroenterology, Taizhou Hospital of Zhejiang Province, Taizhou 318001, Zhejiang Province, China
Guo-Liang Ye, Department of Gastroenterology, The Affiliated Hospital of Medicine School, Ningbo University, Ningbo 315021, Zhejiang Province, China
Rui Li, Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China
Co-first authors: Dong Wang and Yan Chen.
Author contributions: Li ZS, Wang D designed the research study; Li ZS, Wang D, Yan Chen, Ji F, Hu JW, Zhou PH, Xu SC, Ying Chen, Ye LP, Ye GL, and Li R performed the research; Li ZS, Wang D and Yan Chen analyzed the data and wrote the manuscript; All authors have read and approve the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Changhai Hospital Institutional Review Board, No. CHEC2017-221.
Clinical trial registration statement: This study is registered at https://classic.clinicaltrials.gov/. The registration identification number is [NCT03418584].
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Data sharing statement: No additional data are available.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhao-Shen Li, Doctor, PhD, Professor, Department of Gastroenterology, Changhai Hospital, No. 168 Changhai Road, Yangpu District, Shanghai 200433, China. changhailzs@126.com
Received: January 17, 2024
Revised: May 9, 2024
Accepted: May 20, 2024
Published online: July 6, 2024
Processing time: 164 Days and 2.6 Hours
Core Tip

Core Tip: Among the ablation therapies, radiofrequency ablation (RFA) and Argon plasma coagulation (APC) have been the preferred method. However, there is no method that can 100% complete ablation success. Cryotherapy has become a rescue technique for patients with failed RFA. Meanwhile, the techniques used and resulting success rates have been variable. Hybrid APC technology combines injection and APC ablation technology, which may become an easier to use alternative method and may be used more widely. A prospective, multicenter study was undertaken to assess the feasibility and safety of ablation treatment, using HybridAPC, in the treatment of Barrett’s esophagus patients in China.